Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sage Therapeutic Com (NQ: SAGE )

5.170 +0.320 (+6.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Beaten-Down Stocks That Still Aren't Worth Buying
These companies aren't bargains at all. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Is Sage Therapeutics a Contrarian Buy?
A regulatory setback weighed heavily on the drugmaker's shares Monday. 
Via The Motley Fool
Why Sage Therapeutics Stock Is Crashing Today
Sage's regulatory win wasn't enough to offset an even bigger regulatory loss. 
Via The Motley Fool
Market Volatility Falls Sharply, S&P 500 Snaps 4-Session Losing Streak
The S&P 500 settled higher on Monday, snapping a four-session losing streak. U.S. stocks have notched sharp gains this year, with the benchmark S&P 500 adding around 17.7% in 2023. As far as the... 
Via Benzinga
Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P... 
Via Benzinga
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
What 10 Analyst Ratings Have To Say About Sage Therapeutics
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Dow Rises Over 300 Points To Start The Week
The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses. 
Via Talk Markets
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Crude Oil Down Over 1%; Henry Schein Earnings Top Views
U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 7, 2023
Via Benzinga
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories
Benzinga 
Via Benzinga
Why Sage Therapeutics Shares Are Sinking Monday
Sage Therapeutics Inc (NASDAQ: SAGE) shares are trading lower Monday after the company announced the FDA issued a Complete Response Letter (CRL) for one of the company's 
Via Benzinga
SOVO Stock Alert: Campbell Soup Is Buying Sovos Brands for $2.7 Billion
Sovos Brands (SOVO) stock is rising higher on Monday following news that Campbell Soup (CPB) is acquiring the Italian sauces company. 
Via InvestorPlace
Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results
U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to... 
Via Benzinga
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today?
Sage Therapeutics (SAGE) stock isn't doing the best on Monday after the FDA weighed in on the company's depression drug zuranolone. 
Via InvestorPlace
Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug
The company gained approval for the first oral treatment for postpartum depression. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with  
Via Benzinga
Wayfair To Rally Over 32%? Here Are 10 Other Analyst Forecasts For Monday
Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to... 
Via Benzinga
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.